A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
Public ClinicalTrials.gov record NCT00402233. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo. Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and nighttime sleep compared to placebo; to compare the tolerability among the treatment groups over 12 weeks
Study identification
- NCT ID
- NCT00402233
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 312 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 31 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2006 (Type not available)
- Primary completion
- Sep 2008 (Actual)
- Completion
- Not listed
- Last update posted
- May 16, 2014
Started 2006
United States locations
- U.S. sites
- 39
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 248.622.170 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 248.622.112 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 248.622.69 Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| 248.622.198 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 248.622.111 Boehringer Ingelheim Investigational Site | Oxnard | California | — | — |
| 248.622.61 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 248.622.23 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 248.622.73 Boehringer Ingelheim Investigational Site | San Francisco | California | — | — |
| 248.622.108 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 248.622.190 Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| 248.622.215 Boehringer Ingelheim Investigational Site | Manchester | Connecticut | — | — |
| 248.622.196 Boehringer Ingelheim Investigational Site | Boca Raton | Florida | — | — |
| 248.622.14 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 248.622.149 Boehringer Ingelheim Investigational Site | Weston | Florida | — | — |
| 248.622.139 Boehringer Ingelheim Investigational Site | Honolulu | Hawaii | — | — |
| 248.622.5 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 248.622.138 Boehringer Ingelheim Investigational Site | Springfield | Illinois | — | — |
| 248.622.87 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 248.622.207 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 248.622.132 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 248.622.17 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 248.622.40 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 248.622.76 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 248.622.186 Boehringer Ingelheim Investigational Site | East Lansing | Michigan | — | — |
| 248.622.77 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 248.622.155 Boehringer Ingelheim Investigational Site | Lebanon | New Hampshire | — | — |
| 248.622.135 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 248.622.216 Boehringer Ingelheim Investigational Site | Kingston | New York | — | — |
| 248.622.202 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.622.86 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 248.622.1 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 248.622.89 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 248.622.20 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 248.622.169 Boehringer Ingelheim Investigational Site | Hershey | Pennsylvania | — | — |
| 248.622.18 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 248.622.199 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.622.7 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 248.622.213 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 248.622.104 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00402233, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2014 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00402233 live on ClinicalTrials.gov.